Back to Blog

How to overcome Pharma’s Innovation Gap?

Pharmaceutical companies face many challenges in developing new medicines and treatments, including limited resources and slow regulatory processes. To bridge this innovation gap,...

by Jose Zea•4 min read

Pharmaceutical companies face many challenges in developing new medicines and treatments, including limited resources and slow regulatory processes. To bridge this innovation gap, startups leverage technologies like artificial intelligence (AI) to improve access to therapies and increase adherence. By making it easier for patients to access treatments and stick to their treatment plans, startups can improve patient outcomes and reduce healthcare costs. Startups are also disrupting traditional pharma practices by developing innovative delivery systems that make it easier for patients to access treatments faster, cheaper, and better.

Despite the benefits of innovation, many pharmaceutical companies are reluctant to switch their focus and risk losing their competitive edge. This lack of innovation has left many patients without access to timely treatments and cutting-edge technologies. Startups are fighting the innovator's dilemma by taking a more disruptive approach to developing new solutions, which can lead to better outcomes for patients and better returns for investors. With startups driving innovation in the pharma industry, patients can expect to benefit from new treatments and therapies that improve their quality of life.

No alt text provided for this image

Startups can help the pharma innovation gap

Startups can help bridge the innovation gap in the pharmaceutical industry by leveraging new technologies, taking a more disruptive approach, and focusing on patient needs. One way startups are doing this is by improving access to therapies. By leveraging technologies like AI, startups can make it easier for patients to access treatments faster, cheaper, and better. This includes enabling patients to receive remote care, helping doctors consider options that might have been missed otherwise, and developing innovative delivery systems that make it easier for patients to access treatments without having to go through long processes or wait long periods.

Likewise, startups can also help increase treatment adherence, which is a major problem in the pharmaceutical industry. Patients often have difficulty following their prescribed treatment plans, which can lead to reduced effectiveness of drugs, prolonged recovery periods, and higher costs for both patients and healthcare providers. Startups are developing digital health solutions like reminders for pills, drop-out predictions, rewards for healthy behavior, and tracking apps that allow patients to monitor their progress over time. By making it easier for patients to stick to their treatment plans, startups can improve patient outcomes and reduce healthcare costs.

How can AI help in the innovation gap of pharmaceutical companies?

AI can help bridge the innovation gap in the pharmaceutical industry by improving the drug discovery process, accelerating clinical trials, and improving access to therapies.

  • AI can analyze large amounts of data and identify potential drug candidates faster and more accurately than traditional methods. This can speed up the drug discovery process, reduce costs, and increase the chances of success in clinical trials.
  • AI can identify patients more likely to respond positively to a particular treatment, helping researchers design more effective trials, reduce costs, and accelerate the development of new treatments.
  • AI-powered tools like chatbots and telemedicine can enable patients to receive medical advice and support from the comfort of their own homes. This can reduce the burden on healthcare systems, improve patient outcomes, and increase access to care for people in remote or underserved areas.
No alt text provided for this image

Pharma companies that have incorporated AI into their innovation processes.

Several pharmaceutical companies in recent years have incorporated AI into their innovation processes. Here are some examples:

  • Pfizer: In 2016, Pfizer announced a partnership with IBM Watson Health to develop an AI-powered platform for clinical trial matching. The platform uses natural language processing to match cancer patients with appropriate clinical trials based on their medical records.
  • Novartis: In 2019, Novartis announced a collaboration with Microsoft to develop an AI platform for drug discovery and development. The platform uses machine learning algorithms to identify new drug targets and optimize the clinical trial design.
  • Roche: In 2021, Roche acquired an AI startup called GenMark Diagnostics to expand its portfolio of personalized medicine solutions. GenMark's AI-powered platform analyzes patient data to help doctors make more informed treatment decisions.

Conclusion

In conclusion, startups are playing a crucial role in bridging the innovation gap in the pharmaceutical industry by leveraging new technologies, taking a more disruptive approach, and focusing on patient needs. By improving access to therapies and increasing treatment adherence, startups can improve patient outcomes and reduce healthcare costs. Additionally, AI can be a valuable tool in the pharmaceutical industry by improving the drug discovery process, accelerating clinical trials, and improving access to therapies. Some pharmaceutical companies have already incorporated AI into their innovation processes, which can lead to better outcomes for patients and better returns for investors. Collaboration between startups and pharmaceutical companies can drive innovation and bring new treatments and therapies to patients.

References:

  1. IBM and Pfizer to Accelerate Immuno-oncology Research with Watson for Drug Discovery | Pfizer. (s. f.). https://www.pfizer.com/news/press-release/press-release-detail/ibm_and_pfizer_to_accelerate_immuno_oncology_research_with_watson_for_drug_discovery
  2. Novartis and Microsoft announce collaboration to transform medicine with artificial intelligence. (s. f.). Novartis. https://www.novartis.com/news/media-releases/novartis-and-microsoft-announce-collaboration-transform-medicine-artificial-intelligence
  3. Ltd, R. H. F. (2021, 15 marzo). Roche signs definitive merger agreement with GenMark Diagnostics, Inc., to access novel technology to test for broad range of pathogens with one patient sample. GlobeNewswire News Room. https://www.globenewswire.com/news-release/2021/03/15/2192442/0/en/Roche-signs-definitive-merger-agreement-with-GenMark-Diagnostics-Inc-to-access-novel-technology-to-test-for-broad-range-of-pathogens-with-one-patient-sample.html

‍

‍